Streamlining Randomized Clinical Trials for Device Therapies in Heart Failure: Bayesian Borrowing of External Data

Area of Science:

• Cardiovascular Medicine
• Medical Device Technology
• Biostatistics

Background:

• The US Food and Drug Administration's Breakthrough Devices Program expedites novel medical technologies.
• The Optimizer Smart System, a device for heart failure, received FDA approval in 2019.
• Heart failure management remains a critical area for medical innovation.

Purpose of the Study:

• To evaluate the Optimizer device's efficacy in heart failure patients.
• To demonstrate the utility of Bayesian borrowing in clinical trials.
• To assess the device's therapeutic benefit compared to standard medical therapy.

Main Methods:

• A pivotal randomized clinical trial (FIX-HF-5C) was conducted.
• Bayesian borrowing of external data was employed to reduce sample size.
• Statistical methodologies, regulatory aspects, and results interpretation were detailed.

Main Results:

• The Optimizer device showed therapeutic benefit in the FIX-HF-5C trial.
• Bayesian borrowing facilitated a smaller sample size while determining efficacy.
• The trial successfully navigated regulatory pathways for device approval.

Conclusions:

• The FDA Breakthrough Devices Program accelerated device approval.
• Novel Bayesian statistical methods enhanced trial efficiency.
• This approach can serve as a model for future medical device trials.